AMAT: $343.62 ▲ 6.35 (1.88%)CAT: $694.11 ▼ -6.58 (-0.94%)JNJ: $243.73 ▲ 1.69 (0.70%)LRCX: $214.23 ▲ 4.74 (2.26%)MRK: $115.89 ▼ -0.02 (-0.02%)MU: $422.50 ▲ 17.15 (4.23%)XOM: $154.48 ▲ 0.95 (0.62%)CRM: $193.54 ▼ -5.74 (-2.88%)IBM: $246.50 ▼ -1.18 (-0.48%)MSFT: $397.81 ▼ -4.05 (-1.01%)NFLX: $94.75 ▲ 0.44 (0.47%)ORCL: $155.20 ▼ -3.96 (-2.49%)PLTR: $149.79 ▼ -3.71 (-2.42%)AAL.L: $3,188.00 ▼ -65.00 (-2.00%)ASM.AS: $693.00 ▼ -14.80 (-2.09%)ASML.AS: $1,188.00 ▲ 7.60 (0.64%)AZN.L: $14,372.00 ▲ 8.00 (0.06%)BAYN.DE: $39.04 ▼ -0.10 (-0.24%)ENGI.PA: $27.72 ▲ 0.36 (1.32%)ENR.DE: $145.95 ▼ -6.70 (-4.39%)GLEN.L: $525.50 ▼ -5.70 (-1.07%)HSBA.L: $1,188.20 ▼ -7.60 (-0.64%)NOVN.SW: $121.80 ▲ 0.96 (0.79%)RIO.L: $6,750.00 ▼ -95.00 (-1.39%)ROG.SW: $321.20 ▲ 3.00 (0.94%)RR.L: $1,238.00 ▼ -45.50 (-3.54%)RWE.DE: $57.40 ▲ 1.80 (3.24%)SU.PA: $251.60 ▼ -3.15 (-1.24%)TTE.PA: $71.95 ▲ 1.55 (2.20%)ULVR.L: $4,819.00 ▼ -8.50 (-0.18%)NEM: $110.53 ▼ -3.96 (-3.45%)XAUUSD: $5,063.66 ▼ -15.60 (-0.31%)WDC: $270.19 ▲ 9.01 (3.45%)CVX: $195.54 ▼ -1.43 (-0.73%)INTC: $45.93 ▲ 0.68 (1.49%)LLY: $989.27 ▲ 12.02 (1.23%)WMT: $125.76 ▲ 0.43 (0.34%)ABBN.SW: $67.26 ▼ -0.46 (-0.68%)ALV.DE: $355.40 ▲ 4.90 (1.40%)BNP.PA: $85.49 ▼ -0.31 (-0.36%)ENEL.MI: $9.73 ▲ 0.25 (2.58%)GSK.L: $2,043.00 ▲ 12.00 (0.59%)NESN.SW: $80.85 ▲ 0.83 (1.04%)NG.L: $1,378.15 ▲ 10.15 (0.74%)SHELL.AS: $38.89 ▲ 0.35 (0.91%)SIE.DE: $221.40 ▼ -3.30 (-1.47%)AMGN: $366.61 ▼ -1.18 (-0.32%)COP: $120.18 ▼ -0.08 (-0.07%)PEP: $159.24 ▲ 0.38 (0.24%)VZ: $51.22 ▲ 0.59 (1.17%)ABI.BR: $63.54 ▲ 0.92 (1.47%)TTE: $82.44 ▲ 1.02 (1.25%)COST: $1,005.43 ▲ 2.17 (0.22%)LIN: $497.14 ▲ 6.73 (1.37%)BA.L: $2,304.00 ▲ 6.00 (0.26%)DTE.DE: $33.32 ▲ 0.52 (1.59%)AAPL: $253.34 ▼ -2.42 (-0.95%)NVDA: $181.88 ▼ -1.28 (-0.70%)

Company Details

Revelation Biosciences, Inc.

REVBW - NASDAQ

Identifiants & Marche

Ticker REVBW
ISIN US76135L1199
CIK 0001810560
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
Voir l'evolution du cours Retour